Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease.
BACKGROUND
Parkinson's disease patients commonly suffer from speech and vocal problems including dysarthric speech, reduced loudness and loss of articulation. These symptoms increase in frequency and intensity with progression of the disease). Speech and language therapy (SLT) aims to improve the intelligibility of speech with behavioural treatment techniques or instrumental aids.


OBJECTIVE
To compare the efficacy of speech and language therapy versus placebo or no intervention for speech and voice problems in patients with Parkinson's disease.


METHODS
Relevant trials were identified by electronic searches of numerous literature databases including MEDLINE, EMBASE, and CINAHL, as well as handsearching of relevant conference abstracts and examination of reference lists in identified studies and other reviews. The literature search included trials published prior to 11(th) April 2011.


METHODS
Only randomised controlled trials (RCT) of speech and language therapy versus placebo or no intervention were included.


METHODS
Data were abstracted independently by CH and CT and differences settled by discussion.


RESULTS
Three randomised controlled trials with a total of 63 participants were found comparing SLT with placebo for speech disorders in Parkinson's disease. Data were available from 41 participants in two trials. Vocal loudness for reading a passage increased by 6.3 dB (P = 0.0007) in one trial, and 11.0 dB (P = 0.0002) in another trial. An increase was also seen in both of these trials for monologue speaking of 5.4 dB (P = 0.002) and 11.0 dB (P = 0.0002), respectively. It is likely that these are clinically significant improvements. After six months, patients from the first trial were still showing a statistically significant increase of 4.5 dB (P = 0.0007) for reading and 3.5 dB for monologue speaking. Some measures of speech monotoni city and articulation were investigated; however, all these results were non-significant.


CONCLUSIONS
Although improvements in speech impairments were noted in these studies, due to the small number of patients examined, methodological flaws, and the possibility of publication bias, there is insufficient evidence to conclusively support or refute the efficacy of SLT for speech problems in Parkinson's disease. A large well designed placebo-controlled RCT is needed to demonstrate SLT's effectiveness in Parkinson's disease. The trial should conform to CONSORT guidelines. Outcome measures with particular relevance to patients with Parkinson's disease should be chosen and patients followed for at least six months to determine the duration of any improvement.
School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, Birmingham, UK. c.e.clarke@bham.ac.uk.
Clare P
CP
Herd
Claire L
CL
Tomlinson
Katherine H O
KH
Deane
Marian C
MC
Brady
Christina H
CH
Smith
Catherine M
CM
Sackley
Carl E
CE
Clarke
D004401:Dysarthria / Q000209:etiology / Q000628:therapy*; D006801:Humans; D007808:Language Therapy; D010300:Parkinson Disease / Q000150:complications*; D016032:Randomized Controlled Trials as Topic; D013065:Speech Intelligibility; D013070:Speech Therapy; D057832:Watchful Waiting